Category: Health

Release – Cosmos Health’s Amazon UK Business Surpasses $2 Million in TTM Sales, Up 90%, with a 23% Net Profit Margin; Expects Sales to Grow Approximately 72% to $3.9 Million Over the Next Twelve Months

Posted on by [email protected]
Cosmos Health logo

Research News and Market Data on COSM

Amazon UK sales up 90%: $2.27 million in TTM sales for the twelve months to November 2, 2026, up from approximately $1.19 million in the prior twelve months23% net margin on Amazon UK: the Amazon UK channel generated $525,000 in net profit after all direct channel costs, including Amazon fees, cost of goods, shipping, advertising and VAT116,978 units sold on Amazon UK: an average of approximately 320 units per dayRecord performance: July through October 2026 were the four strongest months to date on Amazon UK, each with sales above $215,000Efficient growth: advertising costs of only 2.4% of Amazon UK sales, with refunds below 1%72% growth expected: the Company expects Amazon UK sales of approximately $3.9 million over the next twelve months, an average of approximately $325,000 per month

CHICAGO, IL / ACCESS Newswire / November 4, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its Amazon UK business, reporting strong sales growth and profitability for the trailing twelve months (“TTM”) from November 1, 2025 to November 2, 2026.

Amazon UK Performance

Over the trailing twelve months, Amazon UK sales reached £1.71 million, or approximately $2.27 million, representing an increase of 90% compared with approximately $1.19 million in the prior twelve-month period. During the same period, the Company sold 116,978 units to customers in the United Kingdom, an average of approximately 320 units per day.

This growth built steadily throughout the year. Monthly sales rose from approximately $144,000 in November 2025 to more than $215,000 in each of the last four months, July through October 2026, the four strongest months in the Company’s history on Amazon UK.

Efficient and Profitable Growth

Importantly, this growth has been achieved efficiently. Advertising costs represented only 2.4% of TTM sales, while refunds remained below 1% of sales. After all direct channel costs, including Amazon fees, cost of goods, shipping, advertising and VAT, Amazon UK generated net profit of approximately £395,000, or approximately $525,000, representing a net margin of approximately 23%. The Company believes these results reflect healthy underlying demand for its products, as well as an efficient and scalable sales channel.

Supporting the Transition to a High-Margin Business Model

Amazon UK has become an integral part of Cosmos Health’s transition to a high-margin business model. The Company believes the channel’s performance demonstrates the level of profitability that its proprietary brands can achieve when sold through efficient online channels.

Outlook

Building on this momentum, the Company expects Amazon UK sales over the next twelve months to grow by approximately 72% compared with the TTM period, to approximately $3.9 million, or an average of approximately $325,000 per month. The outlook is based on the Company’s current sales trends and planned growth initiatives on the platform.

CEO Commentary

Greg Siokas, CEO of Cosmos Health, stated: “Amazon UK is now a multi-million-dollar business for us. Over the past twelve months, sales grew 90% to $2.27 million, and the last four months were our strongest ever on the platform.

“Just as important is the quality of that growth. Advertising was only 2.4% of sales, refunds stayed below 1%, and we generated $525,000 in net profit, representing a net margin of approximately 23%. This is the kind of efficient, profitable growth that supports our transition to a high-margin business model.

“Amazon UK is an integral part of our UK business. Looking ahead, we expect sales on the platform to grow by approximately 72% over the next twelve months, to around $3.9 million. We look forward to providing a broader update on our UK operations in due course.”

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications
[email protected]

Note: Sales, unit and profit figures are based on the Company’s Amazon UK seller platform data. They are unaudited and may differ from amounts in the Company’s financial statements. Net profit and net margin are channel-level operating metrics, calculated after all direct channel costs and before corporate overheads; they are not U.S. GAAP measures. U.S. dollar figures have been converted from British pounds sterling at the exchange rate as of the date of this release. The sales outlook is a forward-looking statement based on management’s current expectations and assumptions; actual results may differ materially.

SOURCE: Cosmos Health Inc.

Release – Ocugen Provides Business Update with Third Quarter 2026 Financial Results

Posted on by [email protected]

Research News and Market Data on OCGN

November 4, 2026

PDF Version

Conference Call and Webcast Today at 8:30 a.m. ET

  • Received Provisional Approval and Priority Designation for OCU400 in The Bahamas
    • Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) to coordinate and manage patient care
    • Progressing site readiness in preparation to accept patients
    • Advancing toward full approval and potential patient enrollment as early as year-end
  • Executed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical
  • Initiated dosing in Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA)
  • Cash, cash equivalents, restricted cash, and short-term investments of $84.6 million as of September 30, 2026; with expected runway into 2028

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2026 financial results along with a general business update.

“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen. “As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”

Ocugen continues to advance its three late-stage modifier gene therapy programs toward key clinical and regulatory milestones, with OCU400 expected to be the first Phase 3 study to read out in the first quarter of 2027. The Company remains focused on execution across its pivotal programs while preparing for potential regulatory submissions and broader patient access opportunities.

Clinical Program Updates

OCU400 (RP)

  • Granted Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas; agreement with local partner, GARM, to manage process; site readiness progressing; LARTA final approval and potential patient enrollment as early as year-end
  • Completed an exclusive OCU400 license for MENA with Roots Pharmaceutical. Ocugen is eligible for up to $4 million in combined upfront license fee and potential initial development milestone payments, up to $255 million of potential sales milestones, and a 22% royalty on net sales, and will manufacture commercial supply. It is Ocugen’s second regional OCU400 license agreement, following Kwangdong Pharmaceutical in South Korea
  • Top-line data from the 140-patient Phase 3 liMeliGhT trial are expected in the first quarter of 2027, followed by a planned Biologics License Application (BLA) submission; completed Process Performance Qualification (PPQ) batches to support the BLA and commercial launch supply

OCU410ST (Stargardt disease)

  • Topline data from the Phase 2/3 pivotal confirmatory trial (N=63 subjects) are anticipated in the second quarter of 2027, with a planned BLA submission to follow

OCU410 (GA)

  • Announced the first patient dosed in ArMaDa3, a 240-subject global Phase 3 trial randomizing patients 2:1 to a single subretinal injection of OCU410 or untreated control across the U.S., Canada, and Europe; the primary endpoint is GA lesion growth over 12 months
  • Presented 12-month Phase 2 ArMaDa2 results at three scientific conferences, including two podium presentations at AAO 2026

Corporate Updates

  • Named Jolanda Crombach General Manager of its newly established European affiliate in Amsterdam to support the OCU410 Phase 3 development program, upcoming marketing authorization submissions, and potential commercialization in Europe. Ms. Crombach most recently served as Managing Director and Board Member of Moderna Netherlands and previously held leadership roles at MSD (Merck) and Pfizer

Third Quarter 2026 Financial Results

  • The Company’s cash, cash equivalents, restricted cash, and short-term investments totaled $84.6 million as of September 30, 2026, which is expected to extend the runway into 2028
  • The Company had 339.3 million shares of common stock outstanding as of September 30, 2026
  • Total operating expenses for the three months ended September 30, 2026, were $19.7 million and included research and development expenses of $12.5 million and general and administrative expenses of $7.2 million, compared to total operating expenses for the three months ended September 30, 2025, of $19.4 million that included research and development expenses of $11.1 million and general and administrative expenses of $8.2 million
  • Ocugen reported a $(0.01) net loss per common share for the three months ended September 30, 2026, compared to a $(0.07) net loss per common share for the three months ended September 30, 2025

Conference Call and Webcast Details
Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.

Attendees are invited to participate on the call using the following details:
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 6835403
Webcast: https://edge.media-server.com/mmc/p/w8rytgud (also available on the investor section of the Ocugen website)

A replay of the call and archived webcast will be available on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs, Ocugen’s financial condition and expected cash runway into 2028, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, statements regarding the ability to obtain the full LARTA approval in The Bahamas, and statements regarding the anticipated benefits to Ocugen of the definitive license agreement and supply agreement with Roots Pharmaceutical, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that receipt of Provisional LARTA Approval and Priority Designation may not lead to faster regulatory review and full approval, that the license agreement and supply agreement with Roots Pharmaceutical Company will not lead to the current anticipated benefits to Ocugen, that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts
Investors:
Candice Masse, astr partners
[email protected]

Media:
Chris Clark, Ocugen
[email protected]

View full release here.

NeuroSense Therapeutics Ltd. (NRSN) – New Data To Be Added To Canadian NDS Application For PrimeC

Posted on by [email protected]


Tuesday, November 03, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Additional Data To Strengthen NDS Application. NeuroSense announced it will add data from new analyses of the PrimeC Phase 2b PARADIGM trial to its New Drug Submission (NDS) in Canada. These additional analyses strengthen the application, but have moved the NDS submission date from December 2026 to March 2027. We have not expected this to be a financially important market and do not see this delay as significant.

New, Unpublished Analyses Will Be Included. One of the new analyses to be included in the NDS is data on neurofilament light chain (NfL) levels. This structural protein in neurons serves as a biomarker for neuronal damage and death in ALS. PrimeC patients had greater reductions in NfL than placebo patients, correlating with other clinical findings in the trial. We believe these data further support previous findings of slowed disease progression.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

Posted on by [email protected]

Research News and Market Data on NRSN

Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timeline

Submission would be PrimeC’s first marketing application in any jurisdiction, potentially addressing approximately 4,000 Canadians living with ALS

CAMBRIDGE, Mass., Nov. 2, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced plans to incorporate newly generated data into its New Drug Submission (NDS) to Health Canada for PrimeC, its lead investigational therapy for amyotrophic lateral sclerosis (ALS). The NDS would be PrimeC’s first marketing application in any jurisdiction, and the Company believes the additional data will strengthen the application and expand the evidence available for regulatory review.

The March 2027 filing target updates the previously announced December 2026 timetable, allowing the additional data to be included. Health Canada has confirmed it has no concerns with the revised timing.

The planned filing follows completion of the pre-submission process and alignment with Health Canada on the proposed submission content and structure. The expanded package will combine the Phase 2b PARADIGM results published in JAMA Neurology with a new neurofilament light chain (NfL) analysis and additional unpublished data from the Phase 2b PARADIGM trial. The Company expects the NfL analysis to provide further biomarker evidence supporting the clinical findings observed in PARADIGM. In the new analysis, PrimeC-treated participants demonstrated a greater reduction in NfL compared to placebo, with an even more pronounced effect observed in participants with higher baseline functionality. Additional statistical analyses are underway to further characterize these findings and support their incorporation into the planned submission to Health Canada.

Following acceptance of the NDS for review, Health Canada’s standard review target for an NDS is approximately 300 calendar days. If approved, PrimeC would receive its first regulatory authorization and would address a population of approximately 4,000 Canadians living with ALS, with approximately 1,000 new diagnoses each year. In parallel, the Company is advancing discussions with potential commercialization partners for Canada.

“Neurofilament light chain is one of the most widely used measures of neuronal injury in ALS, and adding this analysis to the PARADIGM results gives Health Canada a broader body of evidence on which to evaluate PrimeC’s potential benefit for people living with ALS,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “Canada is our nearest path to patients, and our priority is to submit the most complete application we can. In parallel, we are preparing for the FDA-cleared U.S. Phase 3 PARAGON trial.”

About NeuroSense

NeuroSense Therapeutics is a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

Results from NeuroSense’s Phase 2b PARADIGM study of PrimeC in ALS have been published in JAMA Neurology.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be conducted primarily in the United States. The Company is working with the FDA on an optimized design for the study.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuronal degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation, with the potential to inhibit disease progression.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes progressive paralysis and, typically, death within 3 years of symptom onset. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “will,” or similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements regarding the Company’s planned New Drug Submission (NDS) to Health Canada for PrimeC, the anticipated timing of such submission, the completion and incorporation of additional clinical and biomarker analyses, including neurofilament light chain (NfL), the potential contribution of such analyses to the regulatory assessment of PrimeC, the anticipated regulatory review process and timelines, the Company’s discussions with potential commercialization partners for Canada, the potential patient population for PrimeC and estimated annual ALS diagnoses in Canada, and the Company’s plans to advance its Phase 3 PARAGON clinical trial in ALS. Forward-looking statements are based on the Company’s current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, delays in completing the additional analyses or preparing and submitting the NDS, the possibility that the additional data may not provide the anticipated supporting evidence, uncertainties regarding the acceptance, review, timing and outcome of the NDS, the possibility that Health Canada may request additional information or clinical studies, delays in initiating or conducting the PARAGON trial, the possibility that the Company will not enter into a commercialization partnership for Canada on acceptable terms, or at all, uncertainty in estimates of ALS incidence and the potential patient population in Canada, the Company’s ability to obtain sufficient financing to support its operations and clinical development programs, the Company’s ability to maintain its listing on Nasdaq and other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission (SEC). There can be no assurance that the NDS will be submitted within the anticipated timeframe, that Health Canada’s review will be completed within the standard review period, or that PrimeC will receive regulatory approval. Additional information concerning these and other risks is included under “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the SEC on March 31, 2026, and in its subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

SOURCE NeuroSense

For further information: Investor Relations and Media Contact: NeuroSense Therapeutics Ltd., [email protected] | +972 (0)9 799 6183

Nutriband (NTRB) – Progress Reported Toward Start Of Clinical Trial

Posted on by [email protected]


Monday, November 02, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Commercial Preparations Continue. Nutriband continues to prepare for the AVERSA Fentanyl clinical trial, now expected to begin in 1H27. The NDA will be submitted through the 505(b)(2) pathway and requires a single Phase 1 trial demonstrating abuse deterrence with AVERSA Fentanyl technology.

Opioid Crisis Is Getting Worse. The Opioid Crisis was declared a National Public Health Emergency in October 2017. While overdose deaths have declined from their 2023 peak, the number of people living with opioid addiction has increased. CEO Garth Sheridan recently appeared in a video with Nick Shirley, a well-known YouTuber. The segment featured a walking tour in Los Angeles, speaking with people who live with fentanyl addiction. The segment can be viewed at https://www.youtube.com/watch?v=zyDQOBp4nn4&t=1357s.  


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Beam Therapeutics Reports Breakthrough Gene-Editing Results as Patients Show Improved Glucose Control

Posted on by [email protected]

Beam Therapeutics (NASDAQ: BEAM) has reported encouraging early clinical results from its experimental gene-editing treatment, BEAM-301, demonstrating the potential to significantly improve glucose regulation in patients with glycogen storage disease type Ia (GSDIa), a rare inherited metabolic disorder.

The Cambridge, Massachusetts-based biotechnology company announced results from its ongoing Phase 1/2 clinical trial on October 27, revealing that two patients receiving the higher treatment dose achieved 15 hours of controlled fasting without requiring the frequent starch supplementation typically necessary to manage the disease.

The findings represent an important early milestone for Beam’s base-editing technology, which is designed to correct specific genetic mutations rather than simply manage symptoms.

GSDIa is a rare genetic condition that prevents the liver from properly converting stored glycogen into glucose. Patients can experience dangerously low blood sugar levels and must carefully manage their diets, often consuming uncooked cornstarch throughout the day and night to maintain stable glucose levels.

BEAM-301 is designed to address the underlying genetic cause of the disease by correcting the R83C mutation in the G6PC1 gene. The treatment uses lipid nanoparticles to deliver gene-editing components directly to the liver.

Unlike traditional treatments that require ongoing medication or dietary management, Beam’s approach aims to provide lasting benefits following a single administration.

The initial clinical results included six patients who received BEAM-301, with three treated at a 20-milligram dose and three receiving 40 milligrams.

In the higher-dose group, the median time patients could fast before experiencing low blood sugar increased from 2.5 hours before treatment to 15 hours at the Day 36 assessment.

Two of the three patients in that group reached the study’s maximum controlled fasting duration of 15 hours. Those same two patients eventually eliminated their daily starch supplementation requirements at their latest reported assessments.

Patients also demonstrated improvements in glucose regulation, providing additional evidence that the treatment may help restore the body’s ability to produce glucose naturally.

However, the study remains in its early stages, and the small number of participants limits conclusions about long-term effectiveness.

Safety findings also warrant continued monitoring. Four of the six patients experienced serious treatment-related adverse events, including infusion reactions. The company reported no dose-limiting toxicities, and the serious events had resolved by the data cutoff.

Beam has modified its premedication and infusion procedures as development continues.

Following the results, the company is advancing BEAM-301 into a higher 60-milligram dose cohort and plans to engage with the U.S. Food and Drug Administration regarding a potential regulatory pathway.

For investors, the announcement offers early clinical evidence supporting Beam’s precision genetic medicine platform. Successful development could establish base editing as a potential treatment strategy for certain inherited metabolic diseases.

The technology differs from conventional gene-editing approaches because it can make targeted changes to individual DNA bases without requiring double-strand DNA breaks.

That distinction could have broader implications for biotechnology companies developing therapies for diseases caused by specific genetic mutations.

Nevertheless, significant clinical and regulatory hurdles remain. Larger studies, longer patient follow-up, and additional safety evaluations will be necessary before BEAM-301 can be considered for approval.

Beam’s latest results highlight the growing potential of next-generation gene-editing treatments while illustrating the substantial development risks associated with bringing innovative therapies to market.

Release – NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC’s Phase 3 Development at NEALS 2026

Posted on by [email protected]

Research News and Market Data on NRSN

Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGON

CAMBRIDGE, Mass., Oct. 29, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a biotechnology company developing treatments for neurodegenerative diseases, today announced that its clinical and biomarker findings informing the next phase of PrimeC’s development will be presented at the 2026 Annual Meeting of the Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium in Clearwater, Florida.

The presentation, titled “From PARADIGM to PARAGON: Converging Clinical and Biomarker Findings Informing Phase 3 Development of PrimeC,” is scheduled for Friday, October 30, at 11:25 a.m. Eastern Time.

The presentation will highlight how clinical and biomarker findings from the PARADIGM Phase 2b program are shaping PARAGON, NeuroSense’s planned Phase 3 study of PrimeC in ALS, supporting a rigorous and more efficient approach to clinical development.

It will be co-presented by Prof. Merit Cudkowicz, MD, MSc, Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Julieanne Dorn Professor of Neurology at Harvard Medical School, and Dr. Shiran Zimri, PhD, Vice President of R&D and Country Lead, Canada, at NeuroSense.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has recently completed analysis of long-term follow-up data from its Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology showing slower functional decline in participants who received PrimeC from study start than in those who initially received placebo. The Company also reported changes across multiple biomarkers associated with ALS, including microRNAs, consistent with PrimeC’s multi-target mechanism of action.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be conducted primarily in the United States. The Company is working with FDA on an optimized design for the study.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation, with the potential to inhibit disease progression.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes progressive paralysis and, typically, death within 3 years of symptoms onset. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the Company’s development program, including for ALS and TBI, the potential issuance, scope and duration of patent protection arising from the Company’s patent application, including expected protection through 2047, subject to any extensions, the potential of PrimeC to treat TBI and related central nervous system injuries, the potential expansion of PrimeC beyond ALS and its potential commercial benefits and long-term value. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. These risks include the risk that the patent application will not result in an issued patent or that any patent granted will not provide the Company with the anticipated scope or duration of protection or will be challenged, invalidated or unenforceable; the risk that PrimeC will not demonstrate safety or efficacy in TBI or related conditions; the potential for delay in the timing of the Phase 3 clinical trial (PARAGON) in ALS; the risk that the Company will not be able to obtain financing on acceptable terms, or at all; the risk that the Company will not regain and maintain compliance with the Nasdaq listing requirements; the risk that non-dilutive grant funding for the PARAGON trial will not be awarded or will be delayed; uncertainty regarding outcomes and the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

SOURCE NeuroSense

For further information: For further information: Email: [email protected] | Tel: +972-(0)9-799-6183

Release – As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated – Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

Posted on by [email protected]

Shelton, Connecticut – Tuesday, October 27, 2026.


NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage leader
developing antiviral drugs that viruses cannot escape, explained today that the Phase IIA Ebola Treatment
Clinical Trial of NV-387 Oral Gummies is progressing well, and the drug is expected to advance into the
Phase IIB clinical trial part as soon as the Phase IIA part is completed.

“The importance of the NV-387 Oral Gummies treatment for this Ebola Bundibugyo virus disease
cannot be understated, considering the potential of the disease for rapid spread and the heavy toll it is
taking in affected areas in terms of both deaths and economic costs of containment and response,” said
Anil R. Diwan, PhD, President and Executive Chairman of the Company.

The NV-387 Oral Gummies as a Treatment for Ebola Phase II Clinical Trial in DRC is divided
into two parts. The first part, Phase IIA, is designed to evaluate dosing regimens based on the severity of
the disease, and requires approximately 20 patients. Enrollment began on September, 23, 2026. The end
point is 28-day survival, as with other Ebola clinical trials. As such, the Phase IIA part will be completed
once the last enrolled person completes 28 days.

The course of the clinical trial suggests that the trial will continue into Phase IIB part upon completion of
the Phase IIA part.

Ebola has escaped the main epidemic affected country of Democratic Republic Congo (DRC) in
multiple instances, and cases have started occurring in Kenya as well as Nigeria, one of the most
populous countries in Africa . Previously, an infected person had traveled from DRC to Uganda, causing 1
a small outbreak, but there have been no new cases reported in Uganda recently. A person that traveled
recently from DRC to Kenya died, and infected at least 8 others, one of whom has also died, and at least
134 contacts were traced . Kenya has released some of the quarantined contacts. The case in Nigeria was 2
a Swiss national and was evacuated to a Swiss hospital for treatment. Previously, medical personnel
working with the Doctors Without Borders (MSF/DWB) have been evacuated to Europe for treatment.

This East to West Africa spread has occurred in spite of substantive travel restrictions. Additional
restrictions have been effected by many countries as a result . Importantly, the instances of single 3
infected persons creating multiple cases have demonstrated the significant global risk and challenge posed
by this Ebola outbreak. As many as 8 or more cases have occurred from contact with a single infected
person during this outbreak. Such persons causing a large number of transmissions are often called
“superspreaders”.

As the outbreak continues, the number of confirmed cases in DRC have reached 10,060, with
4,887 deaths since this Ebola-Bundibugyo virus outbreak was identified. It is the fastest growing Ebola
outbreak, and largest in DRC, with the potential to eclipse, in a few months, the West Africa 2014-16
Ebola-Zaire outbreak that killed 11,000 people.

A clinical trial of Infusions of an antibody cocktail, Infusion of remdesivir, and Infusion of both
of them given to the patient is in progress, called the “PARTNERS” clinical trial, since July 2, 2026.
There have been no public updates, other than that more than 350 patients were already enrolled about a
month ago.

A clinical trial to evaluate vaccines, called “Tumaini” (meaning “Hope” in Swahili) has started as
of last week. The first candidate vaccine in this trial is Ervebo, which is specific to Ebola Zaire, and it is
not known how effective it could be against Ebola Bundibugyo virus. Two other vaccine candidates, one
developed by University of Oxford, ChAdOx1-BDBV, and another, a BDBV-mRNA vaccine developed
by Moderna, are expected to be added into this clinical trial when the supplies become available . This 4
vaccines trial will employ a “ring vaccination” protocol.

Ervebo vaccine is not specific to BDBV, which means it is an unmatched vaccine. Unmatched
Page 1 of 4vaccines can cause rapid occurrence of escape mutants. Also, in vaccinated persons, later infection can
even cause a more aggressive disease, a phenomenon called “Antibody-Dependent Enhancement” of
disease, promoted by the inaccurate antibodies created in response to the vaccine. Vaccines in general can
lead to escape mutants. Ebola virus is an RNA virus and thus very capable of generating escape mutants.
Vaccines are not useful for a person after infection. Also, a vaccine requires about 2-3 weeks for
antibody response to be generated, and therefore is minimally protective before 3 weeks. If a second dose
of vaccine is needed, it complicates the situation further, because the first dose only creates partial
immunity.

Thus an effective treatment is essential for combatting a spreading epidemic such as the current
Ebola epidemic. Infusions such as of antibody cocktails or small chemical drugs are only useful, if
effective, when patients can be hospitalized for the duration until recovery, and are costly to store,
transport, and administer. Thus, to combat a widely spreading disease in the community, oral drugs are the
most preferred.

There is no treatment or vaccine approved for Ebola BDBV at present. NV-387 Oral Gummies is
the only oral drug product in clinical trials, to the best of our knowledge, underscoring its importance for
fighting the current Ebola BDBV epidemic, and future epidemics.
The same drug product, NV-387 Oral Gummies, is also in a Phase II clinical trial for the
treatment of Mpox (Monkeypox) in DRC.

NV-387 is a novel, revolutionary broad-spectrum antiviral that is poised to change the way
humanity treats viral infections.

ABOUT NANOVIRICIDES
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating
special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates
and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of
TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development
of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar
diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several
licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from
TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment
of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox
infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot
project an exact date for filing an IND for any of its drugs because of dependence on a number of external
collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical
trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate
remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir
encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA
approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable.
Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and
NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital
Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform
technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour
licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several
drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases:
Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes
Page 2 of 4Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue
viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The
Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful.
As is customary, the Company must state the risk factor that the path to typical drug development of any
pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts
by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would
show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this
time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful
pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation
regarding future events. Actual events could differ materially and substantially from those projected herein and
depend on a number of factors. Certain statements in this release, and other written or oral statements made by
NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forwardlooking statements since they involve known and unknown risks, uncertainties and other factors which are, in some
cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new information becomes available in the future. Important
factors that could cause actual results to differ materially from the company’s expectations include, but are not
limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the
company from time to time with the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such factors, they may include the following:
demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to
the indications we are seeking; the successful commercialization of our product candidates; and market acceptance
of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research
findings including clinical trials as the customary research usage and do not indicate evaluation of safety or
effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug”
application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and
Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines
Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”.
WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]
Public Relations Contact:
[email protected]
Source: NanoViricides, Inc.

Eledon Pharmaceuticals (ELDN) – Phase 2 BESTOW Analysis Shows Improved Quality Of Life and Reduced Symptom Burden

Posted on by [email protected]


Tuesday, October 27, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Data Presentation On Quality of Life and Symptoms. Eledon presented data from the Phase 2 BESTOW trial at the American Society of Nephrology Annual Kidney Week 2026 meeting. The presentation compared patients receiving tegoprubart with those receiving tacrolimus, showing improvements in quality of life and reductions in symptom burden at 12 months. We believe these findings support prior data on efficacy, safety, and tolerability.

Patient Evaluations. Data from two accepted clinical evaluations, MTSOSD-59R and KDQOL-SF, showed substantial, lasting improvements in quality of life and reductions in transplant-related side effects. We see these patient-reported outcomes as consistent with prior reductions in BPAR (Biopsy-Proven Acute Rejection), improvements in eGFR, and improvements in factors that contribute to long-term graft failure.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Posted on by [email protected]

October 26, 2026

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence

Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus

Results further validate the differentiated clinical profile of tegoprubart and potential to transform standard of care in kidney transplantation

IRVINE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new positive patient-reported outcomes data from the Phase 2 BESTOW clinical trial of tegoprubart, its novel investigational immunosuppression therapy. The data showed significant, sustained improvements in health-related quality of life and symptom burden through 12 months compared with standard of care tacrolimus following kidney transplantation. The results were featured in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 Annual Meeting held October 21-25, 2026, in Denver, Colorado.

“The patient-reported outcomes presented at ASN Kidney Week provide perhaps the clearest picture yet of what tegoprubart’s differentiated profile means for transplant patients in everyday life,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We previously reported encouraging BESTOW results across efficacy, kidney function and safety measures, which alone strengthened our belief in tegoprubart. The additional findings presented demonstrate that these clinical outcomes were accompanied by substantial and importantly sustained improvements in quality of life and reductions in transplant-related symptom burden. Giving transplant patients an effective, safer and more tolerable alternative to tacrolimus addresses one of the most important unmet needs in organ transplantation, and collectively, these data further support the potential of tegoprubart to become a transformative new treatment option for kidney transplant recipients.”

“Success after kidney transplantation is measured not only by preventing rejection and preserving graft function, but also by how patients feel and function in their everyday lives,” said presenting author Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota. “What is particularly compelling about these BESTOW results is the consistency of the patient-reported benefits when treated with tegoprubart compared with tacrolimus following kidney transplant. We observed broad improvements in quality-of-life measures together with remarkably favorable outcomes in transplant-specific symptom reporting. The extent of separation between treatment groups suggests patients receiving tegoprubart may experience meaningful quality of life advantages while maintaining strong clinical outcomes as previously reported from BESTOW.”

Patient-Reported Outcomes Results

Patient-reported outcomes were assessed using the Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) and the Kidney Disease Quality of Life Short Form (KDQOL-SF) Symptoms and Problems Scale, both validated measures of symptom burden. Baseline scores were similar between treatment groups. Collectively, the consistency of findings across both the KDQOL-SF and MTSOSD-59R assessments suggests that reductions in transplant-related symptom burden with tegoprubart may contribute to the improvements observed in patient-reported quality of life and further supports the differentiated clinical profile of tegoprubart compared to tacrolimus observed in the Phase 2 BESTOW clinical trial.

On the MTSOSD-59R assessment, tegoprubart-treated patients reported continued reductions in symptom occurrence from baseline at Months 6 and 12, whereas symptom occurrence in the tacrolimus arm initially declined through Month 6 before returning to slightly above baseline levels at Month 12.

Total MTSOSD-59R
Scores represent symptom occurrence
(higher scores reflect greater symptom occurrence)

Total MTSOSD-59R

CI, confidence interval; KDQOL-SF, Kidney Disease Quality of Life Short Form; MTSOSD-59R, Modified Transplant Symptom Occurrence Scale- 59 Items Revised; SEM, standard error of the mean; tac, tacrolimus; tego, tegoprubart.

Tegoprubart demonstrated greater symptom improvement than tacrolimus in 22 of 23 domains where differential improvement was observed, including neurological, gastrointestinal, metabolic, and physical symptom categories. In addition, tacrolimus demonstrated greater symptom worsening in 22 of 22 domains where differential symptom worsening was observed.

On the KDQOL-SF assessment, kidney transplant patients treated with tegoprubart demonstrated improvements from baseline across all five subscales through Month 12. In the KDQOL-SF scale, a change of 3-5 points can be considered clinically significant, and tegoprubart was thus associated with a clinically and statistically significant improvement in the symptoms and problems subscale compared with tacrolimus at Month 12, with mean changes from baseline of 9.0 and 3.3 points, respectively (p<0.05). Consistent with these findings, the SF-12 mental component summary score increased by 1.5 points in the tegoprubart arm compared to a decline of 1.6 points in the tacrolimus arm, representing a 3.1-point between-group difference.

KDQOL-SF: Change from Baseline

a Higher scores indicate better HRQoL; a change of 3–5 points can be considered clinically significant1. Baseline values were similar across all outcomes. *p < 0.05. HRQoL, health-related quality of life; KDQOL-SF, Kidney Disease Quality of Life Short-Form instrument; SEM, standard error of the mean; SF-12, 12-item short-form survey; tac, tacrolimus; tego, tegoprubart.1. KDOQI. Am J Kidney Dis 2007;50:471–530.

Details of the oral presentation at ASN Kidney Week 2026 are below:

Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients
Presenter: Andrew B. Adams, M.D., Ph.D., Department of Surgery, University of Minnesota Medical School; Minneapolis, Minnesota
Abstract Publication Number: FR-OR084
Session Title: The Changing Landscape of Kidney Transplantation: Clinical Innovation, Outcomes, and Healthy Policy
Session Date and Time: Friday, October 23, 2026, from 4:30 p.m. to 6:00 p.m. MDT
Session Room: Mile High Ballroom 4A (Convention Center)
Presentation Time: 4:40 p.m. to 4:50 p.m. MDT

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Specifically, our ability to achieve our anticipated future development and corporate milestones depends on our ability to obtain additional financing on acceptable terms. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
[email protected]

Eledon Pharmaceuticals Reports Positive Kidney Transplant Trial Data as Tegoprubart Improves Quality of Life

Posted on by [email protected]

Eledon Pharmaceuticals (NASDAQ: ELDN) announced new positive Phase 2 clinical trial results Monday showing that its investigational kidney transplant therapy, tegoprubart, delivered sustained improvements in patient-reported quality of life and transplant-related symptoms compared with tacrolimus, a commonly used immunosuppressive treatment.

The findings, presented at the American Society of Nephrology’s Kidney Week 2026 meeting in Denver, add to previously reported results from Eledon’s Phase 2 BESTOW trial and highlight the potential for a new approach to managing immune suppression following kidney transplantation.

Kidney transplant recipients typically require lifelong immunosuppressive medications to prevent their immune systems from rejecting donated organs. Although existing treatments have significantly improved transplant outcomes, they can produce side effects that affect patients’ daily lives and long-term health.

Eledon’s tegoprubart is designed to address this challenge by targeting CD40 ligand, a protein involved in activating immune responses. Unlike traditional immunosuppressive therapies, the investigational antibody aims to regulate immune activity through a different biological pathway.

The latest BESTOW findings focused on patient-reported outcomes, including physical symptoms, emotional well-being, and overall quality of life during the first year following transplantation.

Researchers evaluated patients using two established assessment tools: the Modified Transplant Symptom Occurrence and Symptom Distress Scale and the Kidney Disease Quality of Life Short Form.

At 12 months, patients receiving tegoprubart demonstrated continued improvements in overall symptom occurrence, while patients treated with tacrolimus experienced a slight worsening compared with their baseline measurements.

Tegoprubart also showed greater symptom improvement in 22 of 23 categories where differences between the treatment groups were observed. These included neurological, gastrointestinal, metabolic, and physical symptoms.

One of the most notable findings involved the Kidney Disease Quality of Life assessment. Patients receiving tegoprubart reported an average nine-point improvement on the Symptoms and Problems Scale, compared with a 3.3-point improvement among patients receiving tacrolimus.

The difference was statistically significant, with Eledon noting that a change of three to five points on the scale can be considered clinically meaningful.

Additional findings suggested potential benefits for mental well-being. Patients treated with tegoprubart experienced a 1.5-point improvement in the mental component summary score, compared with a 1.6-point decline in the tacrolimus group.

The findings suggest that tegoprubart’s potential benefits may extend beyond preventing organ rejection to improving how transplant recipients feel and function in everyday life.

For Eledon, the results provide additional evidence supporting the differentiated clinical profile of its lead drug candidate. Previous BESTOW findings addressed measures of efficacy, kidney function, and safety, while the newly presented data provide further insight into the patient experience.

The development is relevant to investors because kidney transplantation represents a specialized therapeutic market in which effective treatments that reduce medication-related complications could address an important unmet medical need.

However, tegoprubart remains investigational and has not received regulatory approval. Additional clinical development and regulatory review will be necessary before its potential commercial use can be established.

Eledon is also exploring the broader applications of its anti-CD40L technology across other transplantation settings and immune-related conditions, including islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis.

The latest results underscore growing interest in developing more targeted immunosuppressive treatments that balance the prevention of organ rejection with patients’ long-term quality of life.

For small-cap biotechnology investors, Eledon’s findings represent another clinical development milestone as the company works to advance tegoprubart and demonstrate its potential as an alternative to existing kidney transplant therapies.

Take a moment to read more equity research on Eledon Pharmaceuticals here.

Cosmos Health (COSM) – Building a Higher-Margin Healthcare Platform

Posted on by [email protected]


Monday, October 26, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating. We believe Cosmos Health is positioned for a meaningful improvement in profitability as its revenue mix shifts toward higher-margin proprietary healthcare products and pharmaceutical manufacturing. The company’s established wholesale distribution business provides a revenue base, while its expanding U.S. direct-to-consumer operations could become an increasingly important driver of earnings growth.

U.S. direct-to-consumer sales are gaining momentum. Management expects approximately $15 million in fourth-quarter 2026 U.S. e-commerce revenue and $10.5 million in gross profit, reflecting the rapid expansion of its proprietary nutraceutical business. Active U.S. subscriptions reached 8,940 as of October 19, although customer retention and marketing efficiency remain important considerations as the business scales.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Roche Signs $813 Million Zymeworks Cancer Drug Deal as Biotech Partnerships Accelerate

Posted on by [email protected]

Roche is expanding its oncology pipeline through a licensing agreement with Zymeworks (NASDAQ: ZYME) valued at up to $813 million, highlighting continued interest from major pharmaceutical companies in experimental cancer treatments developed by smaller biotechnology firms.

The agreement, announced October 23, 2026, gives Swiss pharmaceutical giant Roche exclusive worldwide rights to develop and commercialize ZW209, an investigational therapy designed to treat certain cancers, including small-cell lung cancer.

Under the agreement, Zymeworks will receive an upfront payment of $55 million, followed by an additional $40 million if Roche initiates a planned Phase 1b clinical trial. The biotechnology company could also receive up to $718 million in development, commercial, and sales-related milestone payments, along with royalties on future sales of approved treatments.

The full $813 million value is contingent on achieving specified milestones and does not represent guaranteed revenue.

ZW209 belongs to an emerging class of cancer therapies known as trispecific T-cell engagers. These treatments are designed to help the immune system recognize and attack cancer cells by connecting immune cells with specific targets found on tumors.

The experimental drug targets DLL3, a protein frequently expressed in small-cell lung cancer and certain other neuroendocrine tumors but generally found at low levels in healthy tissue.

ZW209 is designed to engage DLL3 while simultaneously interacting with two proteins on immune cells, CD3 and CD28. This approach aims to stimulate an immune response against cancer cells while potentially improving the effectiveness and durability of treatment.

The drug remains in early clinical development, and its safety and effectiveness in patients have not yet been established.

Zymeworks will conduct the Phase 1a portion of the clinical program in collaboration with Roche, which will fund the study. Roche will subsequently assume responsibility for global development and commercialization.

The first patient is expected to enter the study before the end of 2026, according to Zymeworks management.

For investors, the transaction illustrates an important strategy in the biotechnology industry: smaller drug developers can use licensing agreements to secure funding and share clinical development risks while retaining opportunities for future milestone payments and royalties.

These partnerships can be particularly valuable for emerging biotechnology companies, where clinical trials require substantial investment and successful commercialization often depends on extensive manufacturing, regulatory, and distribution capabilities.

Roche’s decision to partner on ZW209 before human efficacy data are available also underscores the importance pharmaceutical companies place on differentiated scientific platforms and promising early-stage research.

The agreement reflects broader interest in innovative oncology treatments, including immunotherapies and therapies designed to target specific biological mechanisms involved in cancer.

Within Noble Capital Markets’ research coverage universe, Greenwich LifeSciences (NASDAQ: GLSI) is developing an investigational immunotherapy for breast cancer, while Cardiff Oncology (NASDAQ: CRDF) is advancing onvansertib, an experimental cancer treatment targeting the PLK1 enzyme. Although their technologies differ from ZW209, these companies illustrate the range of oncology approaches being pursued by emerging biotechnology developers. Neither company is involved in the Roche-Zymeworks agreement.

The transaction also highlights the potential financial importance of early-stage biotechnology partnerships. Rather than acquiring entire companies, larger pharmaceutical businesses can license individual drug candidates, gaining access to promising technologies while limiting their initial financial commitments.

However, significant risks remain. Experimental cancer treatments face lengthy clinical trials, regulatory scrutiny, and uncertainty surrounding patient outcomes. Milestone payments depend on future progress, and many investigational therapies never reach commercialization.

The Roche-Zymeworks agreement remains subject to customary closing conditions, including applicable antitrust clearance.

For small-cap biotechnology investors, the deal provides another example of how innovative drug-development platforms can attract major pharmaceutical partners. As competition for differentiated cancer treatments continues, licensing agreements may remain an important source of funding and strategic validation for emerging biotech companies.